[Endovascular therapy of superior vena cava syndrome: clinical case].
The treatment of superior vena cava syndrome is usually oriented to the underlying cause, that can be too slow in emergency cases. We report a 49 years old woman with a multiple myeloma that was admitted due to a superior vena cava syndrome caused by a central venous catheter used for chemotherapy for 20 weeks. She was successfully treated with thrombolysis, angioplasty and stent placement. The patient died 7 months later due to the underlying disease. Long term catheters are the responsible for 20 to 30% of superior vena cava syndromes. Endovascular treatment of the syndrome is successful in 60 to 100% of cases with a symptomatic relapse in 4 to 45% of patients.
Boza
C
C
Sección de Cirugía Vascular y Endovascular, División de Cirugía y Departamento de Enfermedades Cardiovasculares, Facultad de Medicina Pontificia Universidad Católica de Chile.
Mertens
R
R
Valdés
F
F
Kramer
A
A
Mariné
L
L
Vergara
J
J
D000800:Angioplasty, Balloon / Q000379:methods; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use; D015607:Stents; D013479:Superior Vena Cava Syndrome / Q000209:etiology / Q000628:therapy*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator